Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease

Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA

Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy

STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)

Amgen wins European approval for Uplizna in generalised myasthenia gravis

Akeso's AK139 Phase II clinical trials approved in China

Eli Lilly signs definitive agreement to acquire Orna Therapeutics

Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia

AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV

WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals

I Peace generates human iPS cells from NKT cells and offers them for research use

Repertoire Immune Medicines teams up with Eli Lilly and Company to develop tolerizing therapies for autoimmune diseases

Formation Bio acquires worldwide rights to FHND5032 from CTFH

WuXi Biologics collaborates with Sinorda Biomedicine for antibody development

Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE